LPCN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders...

Stats
Today's Volume	19 174.00
Average Volume	64 567.00
Market Cap	25.50M
EPS	$0 ( 2024-03-08 )
Next earnings date	( $-0.680 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.530
ATR14	$0.0630 (1.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-08	Patel Mahesh V.	Buy	4 893	Common Stock
2024-03-08	Fogarty Krista	Buy	991	Common Stock
2023-05-25	Patel Mahesh V.	Buy	8 706	Common Stock
2023-05-10	Papapetropoulos Spyros	Buy	30 000	Stock Option (Right to Buy)
2023-05-10	Higuchi John W.	Buy	30 000	Common Stock (Right to Buy)

INSIDER POWER
93.74
Last 96 transactions
Buy: 4 769 643 \| Sell: 1 163 369

Volume Correlation

Long: -0.03 (neutral)

Short: -0.12 (neutral)

Signal:(62.787) Neutral

Lipocine Inc Correlation

10 Most Positive Correlations
SRTS	0.946
CNDT	0.935
TBNK	0.928
VNET	0.916
KOD	0.915
RUBY	0.915
VTRS	0.915
ATHA	0.914
CRNT	0.912
GTEC	0.912

10 Most Negative Correlations
TYHT	-0.92
CNCE	-0.913
EPZM	-0.897
VERX	-0.886
XOG	-0.883
HSTM	-0.875
CNST	-0.866
BLCT	-0.859
AAON	-0.856
PLPC	-0.853

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lipocine Inc Correlation - Currency/Commodity

0.52
( weak )

0.39
( neutral )

0.00
( neutral )

0.28
( neutral )

-0.08
( neutral )

-0.57
( weak negative )

Lipocine Inc Financials

Annual	2023
Revenue:	$109 987
Gross Profit:	$81 326.00 (73.94 %)
EPS:	$-3.10

FY	2023
Revenue:	$109 987
Gross Profit:	$81 326.00 (73.94 %)
EPS:	$-3.10

FY	2022
Revenue:	$500 000
Gross Profit:	$-8.06M (-1 611.38 %)
EPS:	$-2.07

FY	2021
Revenue:	$16 141.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0000073

Financial Reports:

No articles found.

Lipocine Inc

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.